Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin vs Botox for Glabellar Frown Lines
NCT02096081Phase 4Completed
- Sponsor
- Merz
- Start
- Feb 2014
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of incobotulinumtoxinA in glabellar rhytides (2 arms), sponsored by Merz. Primary endpoint: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment at 1 month. Started Feb 2014; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
glabellar rhytides
Beyond the preview
Go deeper on NCT02096081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02096081.